Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprot...
Main Authors: | Zhou Jun, Ren Zhuoying, Xu Jie, Zhang Jifeng, Chen Y. Eugene |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2021-10-01
|
Series: | Medical Review |
Subjects: | |
Online Access: | https://doi.org/10.1515/mr-2021-0010 |
Similar Items
-
Various Aspects of a Gene Editing System—CRISPR–Cas9
by: Edyta Janik, et al.
Published: (2020-12-01) -
The CRISPR/Cas system: Gene Editing by bacterial defense
by: Amira H. El-Ashry
Published: (2023-09-01) -
Gene editing and therapy – A new tool: CRISPR/Cas9
by: Ashok M. Patil
Published: (2019-07-01) -
Perspectives in Genome-Editing Techniques for Livestock
by: Julia Popova, et al.
Published: (2023-08-01) -
Gene Editing Profiles in 94 CRISPR-Cas9 Expressing T<sub>0</sub> Transgenic Tobacco Lines Reveal High Frequencies of Chimeric Editing of the Target Gene
by: Guo-Qing Song, et al.
Published: (2022-12-01)